CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2XnBHjz
via IFTTT